News

The technology is used to treat glaucoma at the same time as cataract surgery.

STAAR Surgical President and CEO Caren Mason will be retiring December 31, and ophthalmic industry executive Thomas “Tom” G. Frinzi has been tapped as her replacement.

According to the company, RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye.

Company officials point out that RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye.

Runa Capital-led funding will help scale the AI-powered eye pathology detection solution.

Survey of academic chairs and residency directors recognizes centers of excellence in Best Clinical Care, Best Residency, Best Research, and Best Overall Programs.

The decentration and dislocation of lens is key reason for explantation.

Spanish investigators found that local resection may offer better visual results and eye sparing without compromising local tumor control and survival.

Results from our recent poll indicate a mixed bag of responses from ophthalmologists.

Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.

The test is slated for further clinical development in the first quarter of 2023 and, once FDA approved, will be added to the company's catalog of ophthalmological diagnostic tools available to clinicians throughout North America.

Pegcetacoplan is the only GA treatment to demonstrate increased effects over 24 months across a broad patient population.

Stephen Pflugfelder, MD, professor and director of the Ocular Surface Center at Baylor College of Medicine in Houston, Texas, presents a challenging diagnostic dilemma.

Rishi Singh, MD, of Cleveland Clinic Florida, touches upon the various advancements that are making a difference for clinicians and patients and reducing their progression in this disease state.

Julius Oatts, MD, covered a range of current considerations for retinopathy of prematurity (ROP), including the updated International Classification for ROP, clinical research, and some of the socioeconomic factors that affect ROP. Oatts is assistant professor and associate residency program director with the Department of Ophthalmology at the University of California, San Francisco.

The company is poised to roll out its eye-tracking amblyopia treatment to the U.S. market.

Investigators have found that cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.

The American Academy of Ophthalmology has declared December as Safe Toys and Celebrations Month, highlighting how eye-safe toys can help avoid serious eye injuries.

The company anticipates introducing latanoprost ophthalmic solution 0.005% to U.S. eye care practitioners in the second half of 2023.

The drug is expected to be available to eye care clinicians in the US during the second half of 2023.

According to the company, the IDMC recommended continuation of the study based upon the outcome of the futility analysis.

According to the study, attendance improved by 9% and the return on investment totaled $11,387 over a 12-week period.

The IDMC recommended continuation of the study based upon the outcome of the futility analysis.

Harrow Health Inc. announced it has reached an agreement to purchase the exclusive U.S. commercial rights to 5 ophthalmic drugs from Novartis AG for up to $175 million, the company announced today.

Harrow Health Inc. announced it has agreed to purchase the exclusive U.S. commercial rights to 5 ophthalmic drugs from Novartis AG for up to $175 million, the company announced today.

The partnership was formalized at the recent International Conference for Initiatives on Organ and Tissue Donation and Transplantation in Abu Dhabi.

Patients need to pay attention to their eye health over the long term.

The investigators explained that deficient ophthalmologic care is costly to patients, making the identification of groups not receiving adequate care of vital importance